# Bevacizumab and Irinotecan to Treat Brain Tumors

> **NCT00393094** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- High-Grade Gliomas

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00393094
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2010-01
- **Final completion:** 2010-03
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Terminated due to the limitations of accrual.
- **Last updated:** 2012-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393094, "Bevacizumab and Irinotecan to Treat Brain Tumors". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00393094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*